Residential Radon and Small Cell Lung Cancer. Final Results of the Small Cell Study.

Introduction: Residential radon is considered the second cause of lung cancer and the first in never smokers. Nevertheless, there is little information regarding the association between elevated radon levels and small cell lung cancer (SCLC). We aimed to assess the effect of residential radon exposure on the risk of SCLC in general population through a multicentric case-control study.

A qualitative study on a novel peer collaboration care programme during the first COVID-19 outbreak: A SWOT analysis.

Unlabelled: The pandemic has forced nursing teams to incorporate new programmes that modify the organization of care and the use of material resources.

Aims: The purpose of this study was to describe the perspectives of the nursing team about the strengths/opportunities and weaknesses/threats of a novel peer collaboration care programme during the first outbreak of the pandemic.

Design: A qualitative case study with focus groups was conducted in June 2020.

Evaluating health related quality of life in outpatients receiving anti-cancer treatment: results from an observational, cross-sectional study.

Background: The aim of the study was to assess health-related quality of life (HRQOL) in outpatients receiving anti-cancer treatment.

Methods: Observational, cross-sectional, single-center study that assessed HRQOL in cancer patients receiving antineoplastic treatment.

Results: A total of 184 patients were included in the study; the median total FACT-G score was 66 ± 12.

Residential Radon and Small Cell Lung Cancer. Final Results of the Small Cell Study.

Introduction: Residential radon is considered the second cause of lung cancer and the first in never smokers. Nevertheless, there is little information regarding the association between elevated radon levels and small cell lung cancer (SCLC). We aimed to assess the effect of residential radon exposure on the risk of SCLC in general population through a multicentric case-control study.

Cutaneous adverse events in patients receiving anticancer therapy in a tertiary hospital setting: the old and the new.

Background: Targeted therapies and immunotherapies are increasingly prescribed, but classic chemotherapy agents are still highly used in cancer treatment. Both therapies, the old and the new, are associated with cutaneous adverse events (CAEs) that can cause treatment interruptions or reduce the quality of life of patients.

Methods: An observational, cross-sectional, single-center study that included consecutive cancer patients presenting CAEs.

Residential radon and small cell lung cancer. A systematic review.

Residential radon exposure is considered the second cause of lung cancer and the first in never smokers. Nevertheless, the association between the different histological types of lung cancer and radon is not completely clear, and radon effect on small cell lung cancer is not completely understood. We aim to asses the effect of residential radon exposure on the risk of small cell lung cancer (SCLC) in general population and miners through a systematic review applying predefined inclusion and exclusion criteria.

Small Cell Lung Cancer. Methodology and Preliminary Results of the SMALL CELL Study.

Introduction: Small cell lung cancer (SCLC) is the most aggressive histologic type of lung cancer, and accounts for approximately 10%-15% of all cases. Few studies have analyzed the effect of residential radon. Our aim is to determine the risk factors of SCLC.

An eutomer/distomer ratio near unity does not justify non-enantiospecific assay methods in bioequivalence studies.

The aim of the present investigation was to compare the pharmacokinetics of two tablet formulations of 600 mg of racemic ibuprofen obtained using enantiospecific and non-enantiospecific assays, in order to explore if chiral assays should be employed in bioequivalence studies of chiral active substances. The stereoselective assay showed that, for both formulations, there was an initial phase where (R)-ibuprofen was the predominant enantiomer followed by a final phase where (S)-ibuprofen was the predominant one. Results from both analytical methods proved that the two formulations were bioequivalent.